OncoMatch/Clinical Trials/NCT03067051
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Is NCT03067051 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Verteporfin and SpectraCure P18 System for recurrent prostate cancer.
Treatment: Verteporfin · SpectraCure P18 System — The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: external or internal, high dose rate (brachy) radiation therapy — localized prostate cancer
have gone through external or internal, high dose rate (brachy) radiation therapy for localized prostate cancer with histopathologically verified local recurrence
Cannot have received: seed implantation brachytherapy
Patients who have been treated with seed implantation brachytherapy
Lab requirements
Blood counts
granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3
Kidney function
creatinine ≤ 1.5 mg/dl
Liver function
total bilirubin ≤ 1.5 mg/dl, sgot ≤ 3x uln, alt ≤ 3x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify